leisure time -WSS

leisure time

author：explore 2025-08-12 06:45:23 - browse：4

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Sana to lay off nearly a third of staff, de

leisure time

WSS

Sana to lay off nearly a third of staff, de

FDA authorizes Novavax’s updated Covid

Physician executives need more than on

How to fix cancer clinical trials' diversity problem

Stem cell treatment guidelines are released by FDA

Listen: Biogen's potential pivot, & Illumina's next chapter

hotspot

leisure time

leisure time

Cancer drug shortages should be causing more outrage

Advances in CAR

Cancer drug shortages should be causing more outrage

Was Amgen transparent enough on FDA's concern on cancer drug?

As demand for Covid shots wanes, Moderna seeks its next success

What drug price negotiations mean for Medicare Part D

United colonoscopy coverage change 'may cost lives,' doctors say

Bristol 'take

Heart attack and stroke risk calculators need revising

What American doctors can learn from their Israeli counterparts

knowledge

Ethical issues complicate the benefits of medical crowdfunding

Weighted lottery helped low

VC firm General Catalyst wants to buy a health system

Why Charlie Gard's case is so disturbing to Americans

NIH nominee Bertagnolli will get October confirmation hearing

The 10 drugs up first for Medicare price negotiation

Wikipedia

Wikipedia

hotspot

Wikipedia